SARS-CoV-2 nsp14-IN-1

SARS-CoV-2 nsp14-IN-1 (Compound 3) is a prototypic bisubstrate inhibitor of SARS-CoV-2 Nsp14 MTase with an IC50 value of 0.061 μM. SARS-CoV-2 nsp14-IN-1 (Compound 3) has an excellent selectivity profile over a panel of human methyltransferases, can against apanel of 10 human MTases including histone lysine, proteinarginine, and DNA and RNA MTases[1].

Product Specifications

CAS Number

[2816165-02-1]

UNSPSC

12352005

Target

DNA Methyltransferase; Histone Methyltransferase; SARS-CoV

Type

Reference compound

Related Pathways

Anti-infection; Epigenetics

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/sars-cov-2-nsp14-in-1.html

Solubility

10 mM in DMSO

Smiles

O=S(C1=CC=C2C=CC=CC2=C1)(NC[C@H]3O[C@@H](N4C=NC5=C(N)N=CN=C45)[C@H](O)[C@@H]3O)=O

Molecular Formula

C20H20N6O5S

Molecular Weight

456.48

References & Citations

[1]Eunkyung Jung, et al. Bisubstate Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 Nsp14 Methyltransferase. ACS Med. Chem. Lett. July 22, 2022.